CSIMarket
 


Nextcure Inc   (NXTC)
Other Ticker:  
 

Nextcure Inc 's Working Capital Ratio

NXTC's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the forth quarter 2023, Working Capital Ratio fell to 16.38 a new company low.

Within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Working Capital Ratio than Nextcure Inc in forth quarter 2023. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2023 to 133, from total ranking in the third quarter 2023 at 212.

Explain Working Capital Ratio
How much in Current Assets NXTC´s has?
What is the value of NXTC´s Current Liabilities?


NXTC Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -24.59 % 11.22 % 37.27 % -2.46 % 38.12 %
Y / Y Current Assets Change -31.26 % -30.02 % -29.88 % -28.72 % -28.02 %
Working Capital Ratio MRQ 16.38 18.72 17.3 23.77 17.97
NXTC's Total Ranking # 133 # 212 # 180 # 151 # 163
Seq. Current Liabilities Change 5.05 % -16.21 % 24.8 % -31.35 % 54.93 %
Seq. Current Assets Change -8.12 % -9.32 % -9.15 % -9.19 % -6.46 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 31
Overall Market # 133


Working Capital Ratio Statistics
High Average Low
51.73 30.42 16.38
(Sep 30 2020)   (Dec 31 2023)




Financial Statements
Nextcure Inc 's Current Liabilities $ 7 Millions Visit NXTC's Balance sheet
Nextcure Inc 's Current Assets $ 113 Millions Visit NXTC's Balance sheet
Source of NXTC's Sales Visit NXTC's Sales by Geography


Cumulative Nextcure Inc 's Working Capital Ratio

NXTC's Working Capital Ratio for the trailling 12 Months

NXTC Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -24.59 % 11.22 % 37.27 % -2.46 % 38.12 %
Y / Y Current Assets TTM Growth -31.26 % -30.02 % -29.88 % -28.72 % -28.02 %
Working Capital Ratio TTM 18.88 19.18 21.42 25.25 27.31
Total Ranking TTM # 52 # 3698 # 119 # 2760 # 22
Seq. Current Liabilities TTM Growth 5.05 % -16.21 % 24.8 % -31.35 % 54.93 %
Seq. Current Assets TTM Growth -8.12 % -9.32 % -9.15 % -9.19 % -6.46 %


On the trailing twelve months basis In spite of the year on year decrease in NXTC's Current Liabilities to $6.88 millions, cumulative Working Capital Ratio to 18.88 below the NXTC average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Working Capital Ratio than Nextcure Inc . While Working Capital Ratio overall ranking has improved so far to 52, from total ranking during the twelve months ending third quarter 2023 at 3698.

Explain Working Capital Ratio
How much in Current Assets NXTC´s has?
What is the value of NXTC´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 27
Within the Market # 52


trailing twelve months Working Capital Ratio Statistics
High Average Low
37.65 29.12 18.88
(Dec 31 2020)   (Dec 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Essa Pharma inc   40.75 $ 143.869  Millions$ 3.531  Millions
Verona Pharma Plc  38.57 $ 289.708  Millions$ 7.512  Millions
Xbiotech Inc   33.07 $ 201.718  Millions$ 6.100  Millions
Vistagen Therapeutics Inc   30.76 $ 128.114  Millions$ 4.165  Millions
Morphic Holding inc   28.94 $ 716.928  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.79 $ 6,806.733  Millions$ 244.899  Millions
Lexaria Bioscience Corp   27.22 $ 2.694  Millions$ 0.099  Millions
Belite Bio Inc  24.76 $ 89.940  Millions$ 3.633  Millions
Gh Research Plc  24.49 $ 164.089  Millions$ 6.701  Millions
Mineralys Therapeutics Inc   23.76 $ 249.103  Millions$ 10.482  Millions
Astria Therapeutics inc   22.36 $ 250.942  Millions$ 11.221  Millions
Diamedica Therapeutics Inc   19.86 $ 53.675  Millions$ 2.703  Millions
Edgewise Therapeutics inc   19.50 $ 326.997  Millions$ 16.771  Millions
Structure Therapeutics Inc   19.14 $ 473.608  Millions$ 24.740  Millions
Sagimet Biosciences inc   17.29 $ 96.646  Millions$ 5.589  Millions
Protagonist Therapeutics inc   16.71 $ 355.577  Millions$ 21.274  Millions
Nextcure Inc   16.38 $ 112.725  Millions$ 6.883  Millions
Royalty Pharma Plc  16.29 $ 1,274.193  Millions$ 78.222  Millions
Lyell Immunopharma Inc   16.07 $ 554.686  Millions$ 34.519  Millions
Agios Pharmaceuticals Inc   15.75 $ 833.835  Millions$ 52.947  Millions
Anixa Biosciences Inc   15.19 $ 25.219  Millions$ 1.660  Millions
Keros Therapeutics Inc   14.25 $ 347.293  Millions$ 24.373  Millions
Compass Pathways Plc  13.33 $ 261.296  Millions$ 19.604  Millions
Vyne Therapeutics Inc   12.73 $ 95.963  Millions$ 7.538  Millions
Rallybio Corporation  12.39 $ 114.789  Millions$ 9.263  Millions
Rezolute Inc   12.00 $ 96.085  Millions$ 8.008  Millions
Immuneering Corporation  11.81 $ 89.084  Millions$ 7.545  Millions
Cryoport inc   11.77 $ 536.792  Millions$ 45.610  Millions
Cassava Sciences Inc  11.62 $ 129.633  Millions$ 11.158  Millions
Virios Therapeutics Inc   11.62 $ 4.165  Millions$ 0.359  Millions

Date modified: 2024-03-22T10:58:04+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com